Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR

Oncotarget

Volumn 7, Issue 41, 2016, Pages 66525-66539

  Wu, Mengying ^a   An, Jiahui ^a   Zheng, Qidi ^a   Xin, Xiaoru ^a   Lin, Zhuojia ^a   Li, Xiaonan ^a   Li, Haiyan ^a   Lu, Dongdong ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Hepatoma; LncRNA CUDR; Mutant P53 (N340Q L344R); PKM2

Indexed keywords

LONG NONCODING RNA CUDR; LONG UNTRANSLATED RNA; ONCOPROTEIN; PROTEIN KINASE PIM 1; PROTEIN P53; PROTEIN PKM2; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE PROTEIN; PIM1 PROTEIN, HUMAN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TP53 PROTEIN, HUMAN; UCA1 RNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MOUSE; MUTATION; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA, LONG NONCODING; THYROID HORMONES; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84993661861     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9089     Document Type: Article

References (50)

1. Nguyen TA, Menendez D, Resnick MA, Anderson CW. Mutant TP53 posttranslational modifications: challenges and opportunities.Hum Mutat. 2014; 35:738-55.
2. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A, Harris CC. Integrity of p53 in hepatitis B x antigen-positive and-negative hepatocellular carcinomas.Cancer Res. 1997; 57:426-32.
3. Feitelson MA, Zhu M, Duan LX, London WT. patitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993; 8:1109-17.
4. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014; 25:304-17.
5. Óh Ainmhire E, Quartuccio SM, Cheng W, Ahmed RA, King SM, Burdette JE. Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer. PLoS One. 2014; 9:e89553.
6. Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.Cell. 2014; 157:382-94.
7. Boudreau HE, Casterline BW, Burke DJ, Leto TL.Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells.Br J Cancer. 2014; 110:2569-82.
8. Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH. Mutant p53 regulates Dicer through p63-dependent and-independent mechanisms to promote an invasive phenotype. J Biol Chem. 2014; 289:122-32.
9. Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, Zhang P, Xiao J, Zhang B, et al. Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun. 2013; 4:2667.
10. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR. Small molecule induced reactivation of mutant p53 in cancer cells.Nucleic Acids Res. 2013; 41:6034-44.
11. Wei S, Wang H, Lu C, Malmut S, Zhang J, Ren S, Yu G, Wang W, Tang DD, Yan C. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. J Biol Chem. 2014; 289:8947-59.
12. Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, Virtakoivu R, Cao Y, Sansom OJ,et al. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.J Clin Invest. 2014; 124:1069-82.
13. Zheng T, Wang J, Zhao Y, Zhang C, Lin M, Wang X, Yu H, Liu L, Feng Z, Hu W. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.Nat Commun. 2013; 4:2996.
14. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, Yuan J. Chaperone-mediated autophagy degrades mutant p53.Genes Dev. 2013; 27:1718-30.
15. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.Oncogene. 2014; 33:1601-8.
16. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism.Cancer Lett, 2015; 356:197-203.
17. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ, Hu W, Feng Z. Tumour-associated mutant p53 drives the Warburg effect.Nat Commun. 2013; 4:2935.
18. Li L, Zhang Y, Qiao J, Yang JJ, Liu ZR. Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis.J Biol Chem. 2014; 289:25812-21.
19. Wong N, Ojo D, Yan J, Tang D.PKM2 contributes to cancer metabolism. Cancer Lett. 2015; 356 :184-91.
20. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.Nat Cell Biol. 2012; 14:1295-304.
21. Warnock LJ, Knox A, Mee TR, Raines SA, Milner J. Influence of tetramerisation on site-specific posttranslational modifications of p53: comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther. 2008; 7:1481-9.
22. Dai, C., and Gu, W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010; 16:528-536.
23. Brady, C.A., Jiang, D., Mello, S.S., Johnson, T.M.,Jarvis, L.A., Kozak, M.M., Kenzelmann Broz, D.,Basak, S., Park, E.J., McLaughlin, M.E. Cell. 2011; 145:571-583.
24. Maite Huarte, Mitchell Guttman, David Feldser, Manuel Garber, Magdalena J. Koziol, Daniela Kenzelmann-Broz, Ahmad M. Khalil, Or Zuk, Ido Amit, Michal Rabani, Laura D. Attardi, Aviv Regev, Eric S. Lander,et al. Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response. Cell. 2010; 142:409-419.
25. Garufi A, Pucci D, D'Orazi V, Cirone M, Bossi G, Avantaggiati ML, D'Orazi G.Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis. 2014; 5:e1271.
26. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, Skinner HD, Fitzgerald AL, Osman AA, et al. Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation.Mol Cell. 2014; 54:960-74.
27. Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.Proc Natl Acad Sci U S A. 2014; 111:7006-11.
28. Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.PLoS One. 2013; 8:e61353.
29. Darjus F.Tschaharganeh, Wen Xue, Diego F. Calvisi, Matthias Evert, Tatyana V. Michurina p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. Cell.2014; 158:579-592.
30. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ,et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.Cell. 2013; 155:397-409.
31. Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO.Switching of pyruvate kinase isoform L to m2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS One. 2014; 9:e115036.
32. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y, Lu Z. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014; 53:75-87.
33. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012; 150:685-96.
34. Haiyan Li, Jiao Li, Song Jia, Mengying Wu,Jiahui An,Qidi Zheng,Wei Zhang,Dongdong Lu.miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer.Oncotarget. 2015; 6:31958-31984. doi: 10.18632/oncotarget.5579.
35. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, Nishida N, Koseki J, Mimori K, Gotoh N, Yamamoto H, Doki Y, Mori M, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelialmesenchymal transition.Proc Natl Acad Sci U S A. 2014; 111:15526-31.
36. Xin Gui, Haiyan Li,Tianming Li, Hu Pu, Dongdong Lu. Long noncoding RNA CUDR regulates HULC and β-Catenin to govern human liver stem cell malignant differentiation. Molecular Therapy. 2015; 23:1843-1853.
37. Hu Pu, Qidi Zheng, Haiyan Li, Mengying Wu, Jiahui An, Xin Gui, Tianming Li, Dongdong Lu. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc. Oncotarget. 2015; 6: 40775-40798. doi: 10.18632/oncotarget.5805.
38. Tianming Li, Qidi Zheng, Jiahui An, Mengying Wu, Haiyan Li, Xin Gui, Hu Pu and Dongdong Lu. SET1A Cooperates With CUDR to Promote Liver Cancer Growth and Hepatocyte-like Stem Cell Malignant Transformation Epigenetically. Mol Ther. 2016; 24:261-275.
39. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, Abdulkadir SA . Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene . 2010; 29: 2477-87.
40. Biffi G, Tannahill D, Balasubramanian S. An intramolecular G-quadruplex structure is required for binding of telomeric repeat-containing RNA to the telomeric protein TRF2.J Am Chem Soc. 2012; 134:11974-6.
41. Porro A, Feuerhahn S, Delafontaine J, Riethman H, Rougemont J, Lingner J.Functional characterization of the TERRA transcriptome at damaged telomeres. Nat Commun. 2014; 5:5379.
42. Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z, Wang R. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.PLoS One. 2013; 8:e77293.
43. He X, Bao W, Li X, Chen Z, Che Q, Wang H, Wan XP. The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis.Int J Mol Med. 2014; 33:325-32.
44. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, De W, Wang KM, Wang ZX. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer.Mol Cancer. 2014; 13:92.
45. Ding C, Cheng S, Yang Z, Lv Z, Xiao H, Du C, Peng C, Xie H, Zhou L, Wu J, Zheng S. Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells.Int J Mol Sci. 2014; 15:4060-76.
46. Haiyan Li, Jiahui An, Mengying Wu, Qidi Zheng, Xin Gui, Tianming Li, Hu Pu and Dongdong Lu. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.Oncotarget. 2015; 6:27847-27864. doi: 10.18632/oncotarget.4443.
47. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions.Mol Cell. 2011; 44:667-78.
48. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B,et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.Nature. 2010; 464:1071-6.
49. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014; 25:304-17.
50. Patrone G, Puppo F, Cusano R, Scaranari M, Ceccherini I, Puliti A, Ravazzolo R.Nuclear run-on assay using biotin labeling, magnetic bead capture and analysis by fluorescencebased RT-PCR. Biotechniques. 2000; 29:1012-4.